Published in Clin Infect Dis on October 19, 2011
Management of Cryptococcus gattii meningoencephalitis. Lancet Infect Dis (2014) 1.12
Cryptococcal infections in non-HIV-infected patients. Trans Am Clin Climatol Assoc (2013) 1.07
Phenotypic differences of Cryptococcus molecular types and their implications for virulence in a Drosophila model of infection. Infect Immun (2014) 0.86
Impact of Resistance to Fluconazole on Virulence and Morphological Aspects of Cryptococcus neoformans and Cryptococcus gattii Isolates. Front Microbiol (2016) 0.79
Letter re: Marr editorial. Clin Infect Dis (2012) 0.77
Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis (2011) 2.97
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 7.20
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis (2010) 5.53
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis (2009) 4.59
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med (2008) 4.16
Amphotericin B: time for a new "gold standard". Clin Infect Dis (2003) 4.01
Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis (2007) 3.93
Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis (2003) 3.70
Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell (2005) 3.44
Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect (2012) 3.24
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
Dectin-1 and TLRs permit macrophages to distinguish between different Aspergillus fumigatus cellular states. J Immunol (2006) 2.43
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood (2008) 2.39
Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J Infect Dis (2009) 2.37
Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis (2004) 2.31
Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother (2006) 2.22
LaeA, a regulator of morphogenetic fungal virulence factors. Eukaryot Cell (2005) 2.21
Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother (2007) 2.20
Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg Infect Dis (2009) 2.19
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping. Eukaryot Cell (2006) 2.15
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.11
Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother (2004) 2.09
Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus. J Clin Microbiol (2005) 2.05
Emerging fungal diseases. Clin Infect Dis (2005) 2.03
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood (2003) 2.01
Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis (2010) 1.98
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood (2010) 1.97
Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol (2004) 1.84
Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis (2008) 1.75
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis (2004) 1.74
First contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence for spread of the Vancouver Island outbreak. J Clin Microbiol (2007) 1.70
Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.68
Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.67
GliZ, a transcriptional regulator of gliotoxin biosynthesis, contributes to Aspergillus fumigatus virulence. Infect Immun (2006) 1.61
Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis (2010) 1.58
Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors. Biol Blood Marrow Transplant (2013) 1.58
Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals. Antimicrob Agents Chemother (2004) 1.58
Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients. Clin Infect Dis (2013) 1.57
Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis (2004) 1.55
Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis (2012) 1.55
Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin North Am (2006) 1.49
Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol (2006) 1.47
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol (2012) 1.44
Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol (2007) 1.43
(1-->3) beta -D-glucan assay in the diagnosis of invasive fungal infections. Clin Infect Dis (2006) 1.40
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect (2006) 1.38
Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw (2012) 1.35
Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis (2011) 1.34
Cerebrospinal fluid (1,3)-β-D-glucan detection as an aid for diagnosis of iatrogenic fungal meningitis. J Clin Microbiol (2013) 1.34
Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant (2004) 1.31
Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant (2002) 1.27
Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet (2008) 1.25
Aspergillus ustus infections among transplant recipients. Emerg Infect Dis (2006) 1.21
MyD88 signaling contributes to early pulmonary responses to Aspergillus fumigatus. Infect Immun (2007) 1.20
Healthy human T-Cell Responses to Aspergillus fumigatus antigens. PLoS One (2010) 1.14
Aspergillus fumigatus generates an enhanced Th2-biased immune response in mice with defective cystic fibrosis transmembrane conductance regulator. J Immunol (2006) 1.12
Empirical antifungal therapy--new options, new tradeoffs. N Engl J Med (2002) 1.08
Reproducibility of low galactomannan enzyme immunoassay index values tested in multiple laboratories. J Clin Microbiol (2005) 1.07
Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice. Antimicrob Agents Chemother (2002) 1.07
Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates. Antimicrob Agents Chemother (2010) 1.06
Impact of Aspergillus fumigatus in allergic airway diseases. Clin Transl Allergy (2011) 1.03
Aspergillus section Fumigati typing by PCR-restriction fragment polymorphism. J Clin Microbiol (2009) 1.03
Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis (2007) 1.02
Invasive fungal infections in solid organ transplant recipients. Future Microbiol (2012) 1.01
Differential Aspergillus lentulus echinocandin susceptibilities are Fksp independent. Antimicrob Agents Chemother (2010) 0.99
Methods of in vitro macrophage maturation confer variable inflammatory responses in association with altered expression of cell surface dectin-1. J Immunol Methods (2007) 0.99
Scedosporium/Pseudallescheria infections. Semin Respir Crit Care Med (2004) 0.98
The Outbreak of Cryptococcus gattii in Western North America: Epidemiology and Clinical Issues. Curr Infect Dis Rep (2011) 0.96
Cryptococcus gattii: Emergence in Western North America: Exploitation of a Novel Ecological Niche. Interdiscip Perspect Infect Dis (2009) 0.96
Detection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosis. PLoS One (2012) 0.94
Conidial viability assay for rapid susceptibility testing of Aspergillus species. J Clin Microbiol (2002) 0.93
Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. Diagn Microbiol Infect Dis (2012) 0.90
Cystic fibrosis transmembrane conductance regulator regulates epithelial cell response to Aspergillus and resultant pulmonary inflammation. Am J Respir Crit Care Med (2011) 0.89
Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. Biol Blood Marrow Transplant (2008) 0.88
Aspergillus galactomannan index: a surrogate end point to assess outcome of therapy? Clin Infect Dis (2008) 0.87
Cryptococcus gattii infection in healthy hosts: a sentinel for subclinical immunodeficiency? Clin Infect Dis (2011) 0.87
Resistant Microascus cirrosus pneumonia can be treated with a combination of surgery, multiple anti-fungal agents and a growth factor. Mycopathologia (2006) 0.86
In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network. Antimicrob Agents Chemother (2011) 0.86
Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant (2002) 0.86
Hairpin dsRNA does not trigger RNA interference in Candida albicans cells. Yeast (2010) 0.85
New methods to assess susceptibilities of Aspergillus isolates to caspofungin. J Clin Microbiol (2003) 0.84
Administration of voriconazole in patients with renal dysfunction. Clin Infect Dis (2012) 0.84
Determination of antifungal drug susceptibilities of Aspergillus species by a fluorescence-based microplate assay. J Antimicrob Chemother (2004) 0.83
Phenotypic and genotypic identification of human pathogenic aspergilli. Future Microbiol (2006) 0.83
Human monocytes differentiate into macrophages under the influence of human KPB-M15 conditioned medium. J Immunol Methods (2005) 0.83
Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient. Curr Infect Dis Rep (2006) 0.82
Ochroconis gallopava infection in a patient with chronic granulomatous disease: case report and review of the literature. Med Mycol (2012) 0.81
Invasive fungal bezoar requiring partial cystectomy. Urology (2011) 0.80
Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture? Curr Opin Infect Dis (2002) 0.79
Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis. Curr Opin Infect Dis (2013) 0.79
Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant (2007) 0.78
Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection. Transplantation (2016) 0.78
Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. Am J Health Syst Pharm (2013) 0.77
Empirical versus preemptive antifungal therapy for fever during neutropenia. Clin Infect Dis (2009) 0.77